Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of AstraZeneca PLC regarding a class action lawsuit alleging that the company engaged in insurance fraud in China, leading to legal exposure and potential harm to its business activities in the region [1]. Group 1: Allegations and Legal Context - The class period for the allegations is from February 23, 2022, to December 17, 2024 [1]. - Allegations include that AstraZeneca issued materially false and misleading statements and failed to disclose its involvement in insurance fraud in China [1]. - The lawsuit claims that the legal exposure faced by AstraZeneca in China resulted in the detention of the AstraZeneca China President by law enforcement [1]. - It is asserted that AstraZeneca understated its legal risks, which could materially harm its business activities in China once revealed [1]. Group 2: Shareholder Actions and Deadlines - Shareholders who purchased shares of AZN during the specified class period are encouraged to register for the class action [2]. - The deadline for shareholders to seek lead plaintiff status is February 21, 2025 [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. Group 3: Firm's Mission and Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and engage in good corporate citizenship [3].

Core Viewpoint - AstraZeneca PLC is under investigation for potential securities fraud and unlawful business practices, with implications for its senior executives [1][2]. Group 1: Investigation Details - Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca, focusing on possible securities fraud or unlawful business practices by the company and its executives [1]. - A fraud investigation into AstraZeneca has expanded to include several Chinese government agencies, implicating numerous senior executives [2]. Group 2: Market Reaction - Following the news of the fraud investigation, AstraZeneca's American depositary receipt (ADR) price dropped by $5.16, or 7.22%, closing at $66.27 per ADR on November 5, 2024 [2]. Group 3: Pomerantz LLP Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [3].

Johnson & Johnson (JNJ) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion for the expanded use of the subcutaneous (SC) formulation of Rybrevant (amivantamab) in advanced EGFR-mutated non-small cell lung cancer (NSCLC).The CHMP recommendation is for SC Rybrevant in combination with Lazcluze (lazertinib) for the first-line treatment of patients with advanced NSCLC with EGFR exon 19 deletion (ex19del) or L858R mutation. The C ...

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/astrazeneca-plc-lawsuit- ...

SAN DIEGO, Feb. 4, 2025 /PRNewswire/ -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca PLC (NASDAQ: AZN) securities between February 23, 2022 and December 17, 2024. AstraZeneca describes itself as "a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and Biopharmaceuticals, including Cardiovascul ...

NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN). Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/astrazeneca-plc-loss-submission-form-2/?id=126295&from=3 CLASS PERIOD: February 23, ...

In its upcoming report, Astrazeneca (AZN) is predicted by Wall Street analysts to post quarterly earnings of $1.07 per share, reflecting an increase of 46.6% compared to the same period last year. Revenues are forecasted to be $14.28 billion, representing a year-over-year increase of 18.8%.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Before a compan ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In AstraZenecaTo Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in AstraZeneca between between February 23, 2022 and December 17, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Feb. 2, 2025 /PRNewswire/ ...

NEW YORK, Jan. 31, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/astrazeneca-plc-lawsuit ...

NEW YORK, Jan. 30, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN).Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/astrazeneca-plc-loss-submission-form-2/?id=125749&from=4CLASS PERIOD: February 23, 2022 to ...